“中国新药研发成本的经济学实证研究”由工业和信息化部产业发展促进中心及国家重大科技专项“重大新药创制”项目管理办公室联合资助，于2019年11月开展研究工作。该项目主要是对中国创新药的研发成本及影响因素进行系统地经济学研究，主要开展以下工作：首先是通过建立中国创新药成本研究项目库，运用两阶段统计估计、生存分析及资本资产定价等模型，分别对新药研发实付成本、时间成本以及机会成本在内的总体平均成本进行分析测算。其次是从研发资本成本率、研发周期、研发成功率等维度对新药专项支持项目与全行业项目的研发成本进行比较研究。该项目力争为优化公共资金促进新药研发的投入模式提供实证支撑，并且为优化我国创新药研发环境提供实证支撑。

Economic empirical study on the R&D costs of innovative drugs in China
The project of Economic empirical study on the R&D costs of innovative drugs in China was jointly funded by the Industrial Development and Promotion Center of the Ministry of Industry and Information Technology and the Project Management Office of "Major Innovative Drug Development" under National Science and Technology Major Project. The research was carried out in November 2019.This study conducted a systematic economic study on the R&D costs and influencing factors associated with innovative drugs in China. To be more specific, the project first established a database of the costs of innovative drugs in China. Furthermore, this study utilized two-stage statistical estimation, survival analysis and capital asset pricing models to analyze and measure the overall average R&D cost of drugs, including actual out-of-pocket cost, time cost and opportunity cost. Secondly, the project compared the innovative drugs which were supported by "Major Innovative Drug Development" with the whole industry innovative drugs in terms of R&D capital cost rate, research cycle, R&D success rates, etc. The project will provide empirical evidence for optimizing the investment mode of public funds to promote the R&D of innovative drugs and support for optimizing the R&D environment of innovative drugs in China.